TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
from Dementia Big http://ift.tt/2ihwitx via alcoholic dementia
http://ift.tt/2jyeR4B
No comments:
Post a Comment